Long-acting injectable drug prevents HIV infections | Science | AAAS

Long-acting injectable drug prevents HIV infections | Science | AAAS

Long-acting injection protects from HIV

An antiretroviral injection given every two months prevents men and trans women from becoming infected with HIV, according to results that have not yet been peer-reviewed. The experimental drug, called cabotegravir, protects on a level on par with Truvada, a once-daily pill approved for pre-exposure prophylaxis (PrEP) in the United States. “It’s really exciting,” says epidemiologist Jared Baeten. “It gives another option for people who can’t or don’t want to take daily pills.”

Science | 6 min readReference: HIV Prevention Trials press release